Dopo l'orario di chiusura: 30.78 0.01 +0.03%

Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Tema Etf Trust Tema Obesity Cardiometabolic Etf Borsa (HRTS) Ultime notizie

Tema Etf Trust Tema Obesity Cardiometabolic Etf (HRTS)

Tema Etf Trust Tema Obesity Cardiometabolic Etf Borsa (HRTS) Ultime notizie

Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends

Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Yahoo Finance

5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network

(HRTS) Proactive Strategies - Stock Traders Daily

EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' - Benzinga

Tema Endowment ETF plans to ride Wall Street’s private-asset craze - Pensions & Investments

Stone Ridge 2060 Inflation Protected Longevity Income ETF (LIAU) Chart and Price History 2024 - MarketBeat

An Endowment ETF Plans to Ride Wall Street’s Private-Asset Craze - Bloomberg

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Shares Up 0.1% - Defense World

Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC

HRTS: Generating Alpha In Obesity Treatment (NASDAQ:HRTS) - Seeking Alpha

Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance

HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside - Seeking Alpha

ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - Benzinga

This ETF is trying to satisfy appetites for weight loss stocks - CNBC

ETF IQ: Mutual Fund Managers Have the Luxury to Just Say 'No' - Bloomberg

ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Stock Price Down 1.1% - Defense World

Weight-loss drug forecasts jump to $150 billion as supply grows - The Business Standard

Watch Looking at Next Gen of Weight Loss: Tema ETFs CEO - Bloomberg

Spot Ether ETF: a Crypto Game Changer? - Opto RoW

ETFs to Profit from the Weight Loss Drug Boom - Yahoo Finance

OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com

Investing in the diabesity epidemic: a breakthrough moment - Opto RoW

Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace

Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance

Another thematic ETF launches to target global obesity battle - InvestmentNews

Thematic ETF Winners of the Q1 2024 Earnings Season - ETF Trends

S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com

IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily

The Impact of Bitcoin Halving on Investors and ETFs to Explore - The Globe and Mail

A New Horizon: Horizons ETF Management Canada to rebrand as Global X - The Globe and Mail

The 5 Best Biotech ETFs of 2024 - etf.com

Webcast: How to Invest in the Weight Loss Drug Revolution - ETF Trends

This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance

Is the global battle against obesity an opportunity for investors? - InvestmentNews

First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss - Investor's Business Daily

'Continued innovation' is key when investing in weight loss trend - Yahoo Finance

Weight-Loss Drugs: How Outliers Like Biohaven, Regeneron Are Taking On The Muscle Dilemma In The Obesity Space - Investor's Business Daily

The Truth HRTSETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet

US ETF launches from 16th to 23rd November, 2023 - ETF Express

New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade - MarketWatch

New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - BNN Bloomberg

Be Thankful — It Could Have Been So Much Worse - Bloomberg

Simile a HRTS